Policy / Pricing FDA accelerated approval path needs improvement, says ICER PharmaphorumThe FDA's accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.Policy / PricingRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER. Policy / PricingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly says Foundayo safety confirmed in ACHIEVE-4 trialNext: Obesity’s explosive growth continues as Q1 deals exceed total 2025 value Related Stories Policy / Pricing Decoding Medicare Advantage Coding Intensity pharminent July 1, 2026 Policy / Pricing UK partners with Eli Lilly on obesity plan pharminent June 29, 2026 Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy pharminent June 24, 2026
